Industry Context — Common BS Fingerprints in Medical Devices, Pharma & Biotech
Generic Claims:
advancing human health, breakthrough innovation, life-changing therapies, transforming patient outcomes…
Red Flags:
FDA cleared used interchangeably with FDA approved, clinical claims without published study citations, breakthrough claims for incremental improvements, regulatory status implied but not specified…
Semantic Drift Patterns:
homepage claims breakthrough but pipeline page shows preclinical only, FDA approved claims but only for one indication, marketed broadly, claims clinical evidence but links to poster presentations not published studies, claims global reach but regulatory approvals are single-market…
Proof Expectations:
specific regulatory clearance numbers (FDA 510(k), CE, TGA), published clinical trial results with ClinicalTrials.gov registration, ISO 13485 and GMP certification details, peer-reviewed publication citations…
XTANDI (Astellas Pharma Inc.)
(https://xtandi.com) 📸 Data Snapshot: June 20, 2026Analyze the raw signals below. How would a machine score this business’s credibility?
Here are the exact signals captured from up to six pages of the site — the same raw inputs the evaluation engine analyzed. They are grouped by signal type so you can weigh each the way the machine does.
🏗️ Semantic Structure — heading hierarchy & page identity (Info Density · Commodity Fingerprint)
HOMEPAGE XTANDI® (enzalutamide) | Advanced Prostate Cancer Treatment (https://xtandi.com)
Title
XTANDI® (enzalutamide) | Advanced Prostate Cancer Treatment
Meta
XTANDI® is an androgen receptor inhibitor used for the treatment of 4 types of advanced prostate cancer. See Important Safety Info, Risks, & Benefits.
H1 XTANDI is approved to treat 4 types* of advanced prostate cancer
H2 Real patients. Real XTANDI Xperiences.
H2 Jim Confronts Returning Prostate Cancer
H2 Euvon & Janet: The Power of Support
H2 Mahlon's Journey to Accessing XTANDI
H2 Henry's Journey— One Piece at a Time
H2 Janet's Guide to Caring For Your Loved One—and Yourself
H2 Bring this guide to your next doctor's appointment
H2 Select Safety Information
H2 Sign up for support
H2 Important Safety Information & Use
H2 What should I tell my doctor before taking XTANDI?
H2 How should I take XTANDI?
H2 What are the possible side effects of XTANDI?
H2 The most common side effects of XTANDI include:
H2 What is XTANDI?
H4 You are now leaving XTANDI.com
H4 Are you a U.S. Healthcare Professional?
H4 You are now leaving XTANDI.com
H4 Doctor discussion guide
H4 Sign up for support
H4 Clinical results
H4 Financial support
NAV_HEADER_HEADING_REPEATED_BODY_FOOTER Clinical Trial Results | XTANDI® (enzalutamide) (https://xtandi.com/clinical-trials/)
Title
Clinical Trial Results | XTANDI® (enzalutamide)
Meta
Explore the clinical trial results of XTANDI®, an FDA approved treatment for 4 types of advanced prostate cancer. See Important Safety Info, Risks, and Benefits.
H1 XTANDI is FDA-approved to treat 4 types of advanced prostate cancer
H2 In multiple clinical studies, XTANDI was proven to delay cancer progression and helped men live longer.
H2 Discover more XTANDI resources
H2 Important Safety Information & Use
H2 What should I tell my doctor before taking XTANDI?
H2 How should I take XTANDI?
H2 What are the possible side effects of XTANDI?
H2 The most common side effects of XTANDI include:
H2 What is XTANDI?
H3 Metastatic castration-sensitive prostate cancer (mCSPC)
H3 Metastatic castration-resistant prostate cancer (mCRPC)
H3 Non-metastatic castration-resistant prostate cancer (nmCRPC)
H3 Non-metastatic castration-sensitive prostate cancer (nmCSPC) with high risk of cancer spreading
H3 Real people, real stories
H3 Doctor discussion guide
H3 Possible side effects
H4 You are now leaving XTANDI.com
H4 Are you a U.S. Healthcare Professional?
H4 You are now leaving XTANDI.com
H4 XTANDI slowed disease progression
H4 In the same study, XTANDI helped men live longer (Overall Survival)
H4 Select Safety Information
H4 XTANDI slowed disease progression
H4 In the same study, XTANDI helped men live longer (Overall Survival)
H4 Select Safety Information
H4 XTANDI slowed disease spread
H4 In the same study, XTANDI helped men live longer (Overall Survival)
H4 Select Safety Information
H4 XTANDI + ADT slowed disease progression
H4 XTANDI alone slowed disease progression
H4 Select Safety Information
H4 Doctor discussion guide
H4 Sign up for support
H4 Clinical results
H4 Financial support
H5 Men who took XTANDI + ADT had 61% less risk of their cancer progressing compared to those who took ADT alone.
H5 Men taking XTANDI had a 34% reduction in the risk of death compared with men not taking XTANDI.
H5 In addition, patients receiving XTANDI had a 72% improvement in delaying the time before receiving the next cancer treatment, including chemo, compared with ADT alone.
H5 Number of patients alive at 5 years
H5 Men taking XTANDI had an 83% lower chance of their cancer progressing compared with men not taking XTANDI.
H5 Men taking XTANDI had a 23% reduction in the risk of death compared with men not taking XTANDI.
H5 In addition, men taking XTANDI had a 65% reduction in risk of starting new chemotherapy and also delayed the median time before beginning chemotherapy.
H5 Men taking XTANDI had 71% less risk of their cancer spreading compared with men not taking XTANDI.
H5 Men taking XTANDI had a 27% reduction in the risk of death compared with men not taking XTANDI.
H5 In addition, men taking XTANDI had a 79% reduction in risk of starting their next cancer treatment, including chemo. XTANDI also delayed the median time before men began chemotherapy.
H5 Men taking XTANDI + ADT had a 58% lower chance of their cancer spreading compared with men taking ADT alone.
H5 Men taking XTANDI alone had a 37% lower chance of their cancer spreading compared with men taking ADT alone.
H6 XTANDI + ADT
H6 ADT ALONE
H6 XTANDI + ADT
H6 ADT ALONE
H6 XTANDI + ADT
H6 ADT ALONE
H6 XTANDI + ADT
H6 ADT ALONE
H6 XTANDI + ADT
H6 ADT ALONE
H6 XTANDI + ADT
H6 ADT ALONE
H6 XTANDI + ADT
H6 ADT ALONE
H6 XTANDI
H6 ADT ALONE
NAV_HEADER_HEADING_REPEATED_BODY_FOOTER XTANDI® (enzalutamide) Doctor Discussion Guide (https://xtandi.com/talking-to-your-doctor/)
Title
XTANDI® (enzalutamide) Doctor Discussion Guide
Meta
See the Doctor Discussion Guide, which includes questions for your doctor about certain types of prostate cancer. See Safety Info, Risks, & Benefits.
H1 Questions for your next appointment
H2 Self-assessment
H2 Start a conversation about XTANDI
H2 Discover more XTANDI resources
H2 Important Safety Information & Use
H2 What should I tell my doctor before taking XTANDI?
H2 How should I take XTANDI?
H2 What are the possible side effects of XTANDI?
H2 The most common side effects of XTANDI include:
H2 What is XTANDI?
H3 Patient resources
H3 Real people, real stories
H3 Sign up for support emails and resources
H4 You are now leaving XTANDI.com
H4 Are you a U.S. Healthcare Professional?
H4 You are now leaving XTANDI.com
H4 Doctor discussion guide
H4 Sign up for support
H4 Clinical results
H4 Financial support
NAV_HEADER_HEADING_REPEATED_BODY_FOOTER XTANDI® (enzalutamide) Support Sign Up (https://xtandi.com/support-sign-up/)
Title
XTANDI® (enzalutamide) Support Sign Up
Meta
Sign up to receive educational resources for XTANDI® (enzalutamide). See Important Safety Information, Risks, and Benefits.
H1 Want to learn more about XTANDI? We’re here to help
H2 Discover more XTANDI resources
H2 Important Safety Information & Use
H2 What should I tell my doctor before taking XTANDI?
H2 How should I take XTANDI?
H2 What are the possible side effects of XTANDI?
H2 The most common side effects of XTANDI include:
H2 What is XTANDI?
H3 Frequently asked questions
H3 Real people, real stories
H3 Patient resources
H4 You are now leaving XTANDI.com
H4 Are you a U.S. Healthcare Professional?
H4 You are now leaving XTANDI.com
H4 Doctor discussion guide
H4 Sign up for support
H4 Clinical results
H4 Financial support
📝 The Narrative — clean text per page (Info Density · Semantic Coherence)
HOMEPAGE (https://xtandi.com) XTANDI® (enzalutamide) | Advanced Prostate Cancer Treatment
[H1] XTANDI is approved to treat 4 types* of advanced prostate cancer Learn about these 4 types *metastatic castration sensitive prostate cancer (mCSPC); non-metastatic castration sensitive prostate cancer with high risk of cancer spreading (nmCSPC high-risk BCR); metastatic castration resistant prostate cancer (mCRPC); non-metastatic castration resistant prostate cancer (nmCRPC) [IMG: Patient with family member] [H2] Real patients. Real XTANDI Xperiences. Gain perspectives into the lives of men living with prostate cancer and their family. [IMG: Jim Confronts Returning Prostate Cancer video.] [H2] Jim Confronts Returning Prostate Cancer Watch his story [IMG: Euvon & Janet: Power of support video] [H2] Euvon & Janet: The Power of Support Watch their story [IMG: Mahlon’s Journey to Accessing XTANDI® Video] [H2] Mahlon's Journey to Accessing XTANDI Watch his story [IMG: One piece at a time: Henry’s journey living with mCSPC video] [H2] Henry's Journey— One Piece at a Time Watch his story [IMG: Janet] [H2] Janet's Guide to Caring For Your Loved One—and Yourself Watch her story DOCTOR DISCUSSION GUIDE [H2] Bring this guide to your next doctor's appointment Take charge of your care. This guide is full of questions to ask your doctor about prostate cancer and XTANDI. Get the guide [IMG: Icon: Prostate cancer patient discussing XTANDI® with his doctor] [H2] Select Safety Information XTANDI may cause serious side effects including seizure. If you take XTANDI, you may be at risk of having a seizure. Avoid activities where a sudden loss of consciousness could seriously harm you or someone else. Tell your doctor right away if you lose consciousness or have a seizure. Learn more [IMG: Sign up for support emails and resources] [H2] Sign up for support We’re here for you with tools, tips, helpful information, and resources. Sign up For more information on Financial Support, please call 1-855-898-2634 [IMG: Icon: cellphone] Call now
2444 chars
SUB-PAGE (https://xtandi.com/clinical-trials/) Clinical Trial Results | XTANDI® (enzalutamide)
Clinical Results [H1] XTANDI is FDA-approved to treat 4 types of advanced prostate cancer Looking for study results? Start by selecting a prostate cancer type below. [IMG: XTANDI patient Mark.] Mark, an XTANDI patientand clean water advocate [H2] In multiple clinical studies, XTANDI was proven to delay cancer progression and helped men live longer. [H3] Metastatic castration-sensitive prostate cancer (mCSPC) Prostate cancer that has spread to other parts of the body and responds to hormone therapy or surgical treatment to lower testosterone. [IMG: Icon: Alert] Five-year overall survival outcomes data available XTANDI was studied among 1,150 men with prostate cancer that had spread to other parts of the body and was still responding to hormone therapy or surgery to lower testosterone. These men were divided into two groups: 574 received XTANDI + ADT (androgen deprivation therapy) 576 received ADT alone During the study, all men continued ADT, either hormone therapy or surgery to lower testosterone. [IMG: 61% less risk of cancer progression] [H4] XTANDI slowed disease progression [H5] Men who took XTANDI + ADT had 61% less risk of their cancer progressing compared to those who took ADT alone. [IMG: Lightbulb icon] This means the study found the XTANDI + ADT group had 61% less risk of cancer progressing.* At the time of analysis, progression was seen in 89 out of 576 (16%) men in the XTANDI group, compared to 198 out of 574 (34%) men in the ADT-alone group. Patients whose cancer progressed [H6] XTANDI + ADT [IMG: Red arrow] 16 % [H6] ADT ALONE [IMG: Outline arrow] 34 % *Progression was defined as the cancer getting worse, as measured by scans, or if the patient died for any reason. The median length of time until the cancer got worse was not reached for patients taking XTANDI + ADT because more than half of the men were still alive. As opposed, the median length of time until the cancer got worse was 19 months with ADT alone. The median is not the average, but the middle of a set of numbers. [IMG: 34% reduction in the risk of death] [H4] In the same study, XTANDI helped men live longer (Overall Survival) [H5] Men taking XTANDI had a 34% reduction in the risk of death compared with men not taking XTANDI. [IMG: Lightbulb icon] This means the study found the XTANDI + ADT group had a 34% reduction in the risk of death compared with men not taking XTANDI. At the time of analysis, there were 154 out of 574 (27%) deaths in the XTANDI group, compared with 202 out of 576 (35%) deaths in the ADT-alone group. Patients who experienced a fatal event [H6] XTANDI + ADT [IMG: Red arrow] 27 % [H6] ADT ALONE [IMG: Outline arrow] 35 % The median length of time patients lived after starting treatment was not reached for either treatment arm. The median is not the average, but the middle of a set of numbers. [IMG: 72% improvement in delaying next-treatment] [H5] In addition, patients receiving XTANDI had a 72% improvement in delaying the time before receiving the next cancer treatment, including chemo, compared with ADT alone. [IMG: Icon: Alert] Five-year follow-up on overall survival data Investigators observed the number of patients who were alive around 5 years after patients started their treatment in the study. The study above was not designed to show a difference between the two treatment groups at 5 years. This means that these observations cannot tell us if there are differences in the results because of the treatment patients in each group received. Conclusions cannot be reached on this data, including which treatment is better or worse. Unlike the main analysis shown above, the data did not undergo an additional independent review, and it was not used to support the FDA approval of XTANDI. Please speak with your doctor to better understand what this means for you. [H5] Number of patients alive at 5 years XTANDI + ADT 191 deaths out of 574 men ADT ALONE223 deaths out of 576 men Results may vary. Always talk with your doctor to best understand clinical data. [H4] Select Safety Information XTANDI may cause serious side effects including: seizure, a brain condition called PRES, allergic reactions, heart disease that can lead to death, falls and bone fractures, swallowing problems or choking that can lead to death. Learn more about possible side effects [H3] Metastatic castration-resistant prostate cancer (mCRPC) Prostate cancer that has spread to other parts of the body and no longer responds to a hormone therapy or surgical treatment to lower testosterone. XTANDI was studied in 1,717 men with prostate cancer that had spread to other parts of the body and no longer responded to hormone therapy or surgical treatment to lower testosterone. These men were divided into two groups: 872 received XTANDI + ADT (androgen deprivation therapy) 845 received ADT alone During the study, all men continued ADT, either hormone therapy or surgery to lower testosterone. [IMG: 83% less risk of cancer progression] [H4] XTANDI slowed disease progression [H5] Men taking XTANDI had an 83% lower chance of their cancer progressing compared with men not taking XTANDI. [IMG: Lightbulb icon] This means the study found the XTANDI + ADT group had 83% less risk of cancer progressing.* At the time of analysis, progression was seen in 118 out of 832 (14%) men in the XTANDI group, compared with 320 out of 801 (40%) men in the ADT-alone group. Patients whose cancer progressed [H6] XTANDI + ADT [IMG: Red arrow] 14 % [H6] ADT ALONE [IMG: Outline arrow] 40 % *Progression was defined as the cancer getting worse, as measured by scans, or if the patient died for any reason. The median length of time until the cancer got worse was not reached for XTANDI + ADT vs. 4 months for ADT alone. The median is not the average, but the middle of a set of numbers. [IMG: 23% reduction in risk of death] [H4] In the same study, XTANDI helped men live longer (Overall Survival) [H5] Men taking XTANDI had a 23% reduction in the risk of death compared with men not taking XTANDI. [IMG: Lightbulb icon] This means the study found the XTANDI + ADT group had a 23% reduction in the risk of death compared with men not taking XTANDI. At the time of analysis, there were 368 out of 872 (42%) deaths in the XTANDI group, compared with 416 out of 845 (49%) deaths in the ADT-alone group. Patients who experienced a fatal event [H6] XTANDI + ADT [IMG: Red arrow] 42 % [H6] ADT ALONE [IMG: Outline arrow] 49 % The median overall survival was 35 months for men taking XTANDI + ADT vs. 31 months for ADT alone. The median is not the average, but the middle of a set of numbers. [IMG: 65% reduction in starting new chemotherapy] [H4] [H5] In addition, men taking XTANDI had a 65% reduction in risk of starting new chemotherapy and also delayed the median time before beginning chemotherapy. The median time before beginning chemotherapy was 28 months for men taking XTANDI + ADT vs. 11 months for ADT alone. The median is not the average, but the middle of a set of numbers. Results may vary. Always talk with your doctor to best understand clinical data. [H4] Select Safety Information XTANDI may cause serious side effects including: seizure, a brain condition called PRES, allergic reactions, heart disease that can lead to death, falls and bone fractures, swallowing problems or choking that can lead to death. Learn more about possible side effects [H3] Non-metastatic castration-resistant prostate cancer (nmCRPC) Prostate cancer that has not spread to other parts of the body and no longer responds to a hormone therapy or surgical treatment to lower testosterone. XTANDI was studied in 1,401 men with prostate cancer that had not spread to other parts of the body and no longer responded to hormone therapy or surgical treatment to lower testosterone. These men were divided into two groups: 933 received XTANDI + ADT (androgen deprivation therapy) 468 received ADT alone During the study, all men continued ADT, either hormone therapy or surgery to lower testosterone. [IMG: 71% less risk of cancer spreading] [H4] XTANDI slowed disease spread [H5] Men taking XTANDI had 71% less risk of their cancer spreading compared with men not taking XTANDI. [IMG: Lightbulb icon] This means the study found the XTANDI + ADT group had 71% less risk of cancer spreading.* At the time of analysis, cancer spreading was seen in 219 out of 933 (24%) men in the XTANDI group, compared with 228 out of 468 (49%) men in the ADT-alone group. PATIENTS WHOSE CANCER SPREAD [H6] XTANDI + ADT [IMG: Red arrow] 24 % [H6] ADT ALONE [IMG: Outline arrow] 49 % *Cancer was considered to be spreading if shown by scans or if the patient died for any reason. The median length of time until the cancer spread was 37 months for XTANDI + ADT vs. 15 months for ADT alone. The median is not the average, but the middle of a set of numbers. [IMG: 27% reduction in risk of death] [H4] In the same study, XTANDI helped men live longer (Overall Survival) [H5] Men taking XTANDI had a 27% reduction in the risk of death compared with men not taking XTANDI. [IMG: Lightbulb icon] This means the study found the XTANDI + ADT group had a 27% reduction in the risk of death compared with men not taking XTANDI. At the time of analysis, there were 288 out of 933 (31%) deaths in the XTANDI group, compared to 178 out of 468 (38%) deaths in the ADT-alone group. Patients who experienced a fatal event [H6] XTANDI + ADT [IMG: Red arrow] 31 % [H6] ADT ALONE [IMG: Outline arrow] 38 % The median overall survival was 67 months for men taking XTANDI + ADT vs. 56 months for ADT alone. The median is not the average, but the middle of a set of numbers. [IMG: 79% reduction in risk of starting next treatment] [H4] [H5] In addition, men taking XTANDI had a 79% reduction in risk of starting their next cancer treatment, including chemo. XTANDI also delayed the median time before men began chemotherapy. The median time before beginning chemotherapy was 40 months for men taking XTANDI + ADT vs. 18 months for ADT alone. The median is not the average, but the middle of a set of numbers. Results may vary. Always talk with your doctor to best understand clinical data. [H4] Select Safety Information XTANDI may cause serious side effects including: seizure, a brain condition called PRES, allergic reactions, heart disease that can lead to death, falls and bone fractures, swallowing problems or choking that can lead to death. Learn more about possible side effects [H3] Non-metastatic castration-sensitive prostate cancer (nmCSPC) with high risk of cancer spreading Prostate cancer in men that has not spread to other parts of the body and responds to a hormone therapy or surgical treatment to lower testosterone, and who are at a high risk of cancer spreading to other parts of the body. XTANDI was studied in 1,068 men with prostate cancer: That had not spread to other parts of the body and responds to a hormone therapy to lower testosterone Who are at high risk of cancer spreading to other parts of the body Who had not received chemotherapy and who all had prior surgery or radiation as definitive treatment These men were divided into three groups: 355 received XTANDI + ADT (androgen deprivation therapy) 355 received XTANDI alone 358 received ADT alone The median length of time until the cancer spread was not reached for any treatment arm. Cancer was considered to be spreading if shown by scans or if the patient died for any reason. The median is not the average, but the middle of a set of numbers. [IMG: 58% less risk of cancer spreading with XTANDI® + ADT] [H4] XTANDI + ADT slowed disease progression [H5] Men taking XTANDI + ADT had a 58% lower chance of their cancer spreading compared with men taking ADT alone. [IMG: Lightbulb icon] This means the study found the XTANDI + ADT group had 58% less risk of cancer spreading.* At the time of analysis, cancer spreading was seen in 45 out of 355 (13%) men in the XTANDI + ADT group, compared with 92 out of 358 (26%) men in the ADT-alone group. PATIENTS WHOSE CANCER SPREAD [H6] XTANDI + ADT [IMG: Red arrow] 13 % [H6] ADT ALONE [IMG: Outline arrow] 26 % [IMG: 37% less risk of cancer spreading with XTANDI alone] [H4] XTANDI alone slowed disease progression [H5] Men taking XTANDI alone had a 37% lower chance of their cancer spreading compared with men taking ADT alone. [IMG: Lightbulb icon] This means the study found the XTANDI group had 37% less risk of cancer spreading. At the time of analysis, cancer spreading was seen in 63 out of 355 (18%) men in the XTANDI + ADT group, compared with 92 out of 358 (26%) men in the ADT-alone group. PATIENTS WHOSE CANCER SPREAD [H6] XTANDI [IMG: Red arrow] 18 % [H6] ADT ALONE [IMG: Outline arrow] 26 % This trial is ongoing to determine the effect on overall survival. A medication holiday may be recommended by your doctor. This means you may take a break from your treatment. The length of your break will be determined by your doctor. *Cancer was considered to be spreading if shown by scans or if the patient died for any reason. The median length of time until the cancer spread was not reached for any treatment arm. The median is not the average, but the middle of a set of numbers. Results may vary. Always talk with your doctor to best understand clinical data. [H4] Select Safety Information XTANDI may cause serious side effects including: seizure, a brain condition called PRES, allergic reactions, heart disease that can lead to death, falls and bone fractures, swallowing problems or choking that can lead to death. Learn more about possible side effects [H2] Discover more XTANDI resources [H3] Real people, real stories Hear firsthand from men who
15000 chars
SUB-PAGE (https://xtandi.com/talking-to-your-doctor/) XTANDI® (enzalutamide) Doctor Discussion Guide
Doctor Discussion Guide [H1] Questions for your next appointment [IMG: Doctor discussing XTANDI® with patient.] Your health is a team effort, and you can be a key player. We’ve created this guide full of questions to ask your doctor about advanced prostate cancer and XTANDI® (enzalutimide). Download this guide (PDF) XTANDI possible side effects [H2] Self-assessment [IMG: Icon: Notepad] In addition to living longer, what are your treatment goals? For many people with advanced prostate cancer, these can include: Delaying cancer progression Understanding test results, including PSA Delaying the start of chemotherapy Medication that only has to be taken once a day Understanding treatment options Understanding the side effects Other: ___________________ [H2] Start a conversation about XTANDI [IMG: Icon: Communicate with your doctor] Can XTANDI help patients: Live longer? Delay the progression or spread of cancer? Lower the chances of having to start a new chemotherapy regimen? When is the right time to start XTANDI? Are there benefits of starting XTANDI now? What are the potential side effects? Will my insurance cover XTANDI? Can I get assistance paying for XTANDI? How do I take XTANDI? How often do I need to take XTANDI? Do I need to take XTANDI with food? How extensively has XTANDI been studied, tested, and used in patients? [H2] Discover more XTANDI resources [H3] Patient resources Helpful XTANDI resources for patients and caregivers Explore resources [H3] Real people, real stories Hear firsthand from men who are taking XTANDI Watch their stories [H3] Sign up for support emails and resources We’re here for you with tools, tips, information, and support Sign up
2080 chars
SUB-PAGE (https://xtandi.com/support-sign-up/) XTANDI® (enzalutamide) Support Sign Up
Sign up for support [H1] Want to learn more about XTANDI? We’re here to help For education resources about XTANDI® (enzalutamide), along with helpful information, including patient stories, questions to ask your doctor, and more sent directly to your inbox, fill out the form below. [H2] Discover more XTANDI resources [H3] Frequently asked questions You may have more questions. We have answers! Review FAQs [H3] Real people, real stories Hear firsthand from men who are taking XTANDI Watch their stories [H3] Patient resources Helpful XTANDI resources for patients and caregivers Explore resources
806 chars
🛡️ Trust Signals — reviews, proof links, trust-theatre flag (Trust & Proof)
5Review mentions (all pages)
0External proof links (all pages)
| Page | Reviews | Proof links |
|---|---|---|
| / (home) | 0 | 0 |
| /clinical-trials/ | 3 | 0 |
| /talking-to-your-doctor/ | 0 | 0 |
| /support-sign-up/ | 2 | 0 |
🔗 Identity & Technical Layer — schema JSON-LD: identity chains, entity gaps (Identity & Authority)
Homepage schema
{
"@context": "http://schema.org",
"@type": "MedicalWebPage",
"audience": "https://schema.org/Patient",
"specialty": "https://schema.org/Oncologic",
"url": "https://www.xtandi.com/",
"name": "XTANDI® (enzalutamide) | Advanced Prostate Cancer Treatment",
"headline": "*",
"description": "XTANDI® is an androgen receptor inhibitor (ARI) used for the treatment of four types of advanced prostate cancer, including mCRPC, nmCRPC, mCSPC, and nmCSPC with rapidly rising PSA. See Important Safety Information, Risks, and Benefits.",
"potentialAction": [
{
"@type": "Action",
"name": "Learn more",
"description": "Savings & Support: Find out more information about financial support options that may help eligible patients.",
"url": "https://www.xtandi.com/financial-support"
},
{
"@type": "Action",
"name": "Watch their stories",
"description": "Gain perspective into the lives of men living with advanced prostate cancer and taking XTANDI.",
"url": "https://www.xtandi.com/patient-videos"
},
{
"@type": "Action",
"name": "Watch story",
"description": "The Power of Support",
"url": "https://www.xtandi.com/patient-videos/power-of-support"
},
{
"@type": "Action",
"name": "Watch story",
"description": "Self-Advocating",
"url": "https://www.xtandi.com/patient-videos/self-advocating"
},
{
"@type": "Action",
"name": "Watch story",
"description": "Journey to Access",
"url": "https://www.xtandi.com/patient-videos/journey-to-access"
},
{
"@type": "Action",
"name": "Watch story",
"description": "Advice",
"url": "https://www.xtandi.com/patient-videos/advice"
},
{
"@type": "Action",
"name": "Watch story",
"description": "Treatment",
"url": "https://www.xtandi.com/patient-videos/treatment"
},
{
"@type": "Action",
"name": "Learn more",
"description": "Select Safety Information",
"url": "https://www.xtandi.com/side-effects"
},
{
"@type": "Action",
"name": "Sign up",
"description": "Sign up for support emails and resources",
"url": "https://www.xtandi.com/support-sign-up"
}
],
"about": [
{
"@type": "Drug",
"name": "XTANDI",
"nonProprietaryName": "enzalutamide",
"image": {
"@type": "ImageObject",
"name": "XTANDI® (enzalutamide) 40 mg tablets | 80 mg tablets",
"description": "XTANDI Logo",
"contentUrl": "https://www.xtandi.com/images/xtandi-logo.svg"
},
"description": "What is XTANDI? XTANDI is a prescription medicine used to treat men with prostate cancer that: no longer responds to a hormone therapy or surgical treatment to lower testosterone OR has spread to other parts of the body and responds to a hormone therapy or surgical treatment to lower testosterone OR has not spread to other parts of the body and responds to a hormone therapy or surgical treatment to lower testosterone, and who are at high risk of cancer spreading to other parts of the body. It is not known if XTANDI is safe and effective in females or children.",
"prescribingInfo": "https://www.astellas.us/docs/us/12A005-ENZ-WPI.pdf",
"warning": "What should I tell my doctor before taking XTANDI? Tell your doctor about all your medical conditions, including if you: Have a history of seizures, brain injury, stroke, or brain tumors. Have a history of heart disease, have high blood pressure, or have abnormal amounts of fat or cholesterol in your blood (dyslipidemia). Are pregnant or plan to become pregnant. XTANDI can cause harm to your unborn baby and loss of pregnancy (miscarriage). Have a partner who is pregnant or may become pregnant. Males who have female partners who are able to become pregnant should use effective birth control (contraception) during treatment with XTANDI and for 3 months after the last dose. Males must use a condom during sex with a pregnant female. Are breastfeeding or plan to breastfeed. It is not known if XTANDI passes into your breast milk. Take other medicines. XTANDI may affect the way other medicines work, and other medicines may affect how XTANDI works. These include prescription and over-the-counter medicines, vitamins, and herbal supplements. Do not start or stop any medicine without talking to your doctor. How should I take XTANDI? Take XTANDI exactly as your doctor tells you. Take your prescribed dose once a day, at the same time each day. XTANDI can be taken with or without food. Swallow XTANDI capsules or tablets whole. Do not chew, dissolve, or open the capsules. Do not cut, crush or chew the tablets. Your doctor may change your dose if needed. Do not change or stop taking your prescribed dose of XTANDI without talking with your doctor first. If you are receiving gonadotropin-releasing hormone (GnRH) therapy, you should continue with this treatment while taking XTANDI unless you have had surgery to lower the amount of testosterone in your body (surgical castration). If you miss a dose of XTANDI: Take your prescribed dose as soon as you remember that day. If you miss your daily dose, take your prescribed dose at your regular time the next day. Do not take more than your prescribed dose of XTANDI each day. If you take too much XTANDI: Call your doctor or go to the nearest emergency room right away. You may have an increased risk of seizure if you take too much XTANDI. What are the possible side effects of XTANDI? XTANDI may cause serious side effects including: Seizure. If you take XTANDI, you may be at risk of having a seizure. Avoid activities where a sudden loss of consciousness could seriously harm you or someone else. Tell your doctor right away if you lose consciousness or have a seizure. Posterior Reversible Encephalopathy Syndrome (PRES). If you take XTANDI you may be at risk of developing a condition involving the brain called PRES. Tell your doctor right away if you have a seizure or quickly worsening symptoms such as headache, decreased alertness, confusion, reduced eyesight, blurred vision or other visual problems. Your doctor will do a test to check for PRES. Allergic Reactions. Allergic reactions have happened in people who take XTANDI. Stop taking XTANDI and get medical help right away if you develop swelling of the face, tongue, lip or throat. Heart Disease. Blockage of the arteries in the heart (ischemic heart disease) that can lead to death has happened in some people during treatment with XTANDI. Your doctor will monitor you for signs and symptoms of heart problems during your treatment. Call your doctor or go to the emergency room right away if you get chest pain or discomfort at rest or with activity or shortness of breath during your treatment with XTANDI. Falls and Bone Fractures. XTANDI treatment may increase your risk for falls and bone fractures. Falls were not caused by loss of consciousness or seizures. Your doctor will monitor your risks for falls and bone fractures during treatment with XTANDI. Your doctor will stop treatment with XTANDI if you have serious side effects. The most common side effects of XTANDI include: Muscle and joint pain Feeling more tired than usual Hot flashes Constipation Decreased appetite Diarrhea High blood pressure Bleeding problems Falls Bone fractures Headache XTANDI may cause fertility problems in males, which may affect the ability to father children. Talk to your doctor if you have concerns about fertility. These are not all the possible side effects of XTANDI. For more information, talk to your doctor or pharmacist. Call your doctor for medical advice about side effects. You may report side effects to the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. For further information, please talk to your doctor and click here for Patient Information and Full Prescribing Information for XTANDI.",
"prescriptionStatus": "https://health-lifesci.schema.org/PrescriptionOnly",
"dosageForm": "tablets",
"administrationRoute": "oral",
"doseSchedule": {
"@type": "DoseSchedule",
"frequency": "XTANDI is taken by mouth and is available in 2 dosage strengths: 40 mg and 80 mg. Take XTANDI once a day, at the same time every day, with or without food."
},
"offers": {
"@type": "Offer",
"price": "0",
"priceCurrency": "USD",
"url": "https://www.xtandi.com/"
},
"manufacturer": {
"@type": "Organization",
"name": "Astellas",
"logo": "https://www.xtandi.com/img/logo-astellas.png"
}
}
]
}
/clinical-trials/
{
"0": {
"@context": "http://schema.org",
"@type": "MedicalWebPage",
"audience": "https://schema.org/Patient",
"specialty": "https://schema.org/Oncologic",
"url": "https://www.xtandi.com/clinical-trials",
"name": "Clinical Trial Results | XTANDI® (enzalutamide)",
"headline": "XTANDI is FDA-approved to treat 4 types of advanced prostate cancer",
"description": "Explore the clinical trial results of XTANDI®, an FDA-approved treatment for 4 types of advanced prostate cancer. See Important Safety Information, Risks, and Benefits.",
"mainEntity": [
{
"name": "In multiple clinical studies, XTANDI® (enzalutamide) was proven to delay cancer progression and helped men live longer"
},
{
"@type": "ListItem",
"position": "1",
"name": "Metastatic castration-sensitive prostate cancer (mCSPC)",
"description": "Prostate cancer that has spread to other parts of the body and responds to hormone therapy or surgical treatment to lower testosterone.",
"url": "https://www.adcetris.com/static/adcetris-treatment-decision-guide-d132e78b194b56bc174108130719df76.pdf"
},
{
"@type": "ListItem",
"position": "2",
"name": "Metastatic castration-resistant prostate cancer (mCRPC)",
"description": "Prostate cancer that has spread to other parts of the body and no longer responds to a hormone therapy or surgical treatment to lower testosterone."
},
{
"@type": "ListItem",
"position": "3",
"name": "Non-metastatic castration-resistant prostate cancer (nmCRPC)",
"description": "Prostate cancer that has not spread to other parts of the body and no longer responds to a hormone therapy or surgical treatment to lower testosterone."
}
],
"potentialAction": [
{
"@type": "Action",
"name": "Overall Survival",
"description": "XTANDI helped men live longer",
"url": "https://www.xtandi.com/clinical-glossary?keyword=overall-survival"
},
{
"@type": "Action",
"name": "Learn more",
"description": "XTANDI may cause serious side effects including falls and fractures.",
"url": "https://www.xtandi.com/side-effects"
},
{
"@type": "Action",
"name": "Watch their stories",
"description": "Hear firsthand from men who are taking XTANDI",
"url": "https://www.xtandi.com/patient-stories"
},
{
"@type": "Action",
"name": "Review guide",
"description": "Need to prepare for your next doctor’s visit?",
"url": "https://www.xtandi.com/doctor-discussion-guide"
},
{
"@type": "Action",
"name": "Learn more",
"description": "Explore our glossary of prostate cancer terms",
"url": "https://www.xtandi.com/clinical-glossary"
}
],
"about": [
{
"@type": "Drug",
"name": "XTANDI",
"nonProprietaryName": "enzalutamide",
"image": {
"@type": "ImageObject",
"name": "XTANDI® (enzalutamide) 40 mg tablets | 80 mg tablets",
"description": "XTANDI Logo",
"contentUrl": "https://www.xtandi.com/images/xtandi-logo.svg"
},
"description": "What is XTANDI? XTANDI is a prescription medicine used to treat men with prostate cancer that: no longer responds to a hormone therapy or surgical treatment to lower testosterone OR has spread to other parts of the body and responds to a hormone therapy or surgical treatment to lower testosterone OR has not spread to other parts of the body and responds to a hormone therapy or surgical treatment to lower testosterone, and who are at high risk of cancer spreading to other parts of the body. It is",
"prescribingInfo": "https://www.astellas.us/docs/us/12A005-ENZ-WPI.pdf",
"warning": "What should I tell my doctor before taking XTANDI? Tell your doctor about all your medical conditions, including if you: Have a history of seizures, brain injury, stroke, or brain tumors. Have a history of heart disease, have high blood pressure, or have abnormal amounts of fat or cholesterol in your blood (dyslipidemia). Are pregnant or plan to become pregnant. XTANDI can cause harm to your unborn baby and loss of pregnancy (miscarriage). Have a partner who is pregnant or may become pregnant. ",
"study": [
{
"@type": "[DEPTH_TRUNCATED]",
"name": "[DEPTH_TRUNCATED]",
"trialDesign": "[DEPTH_TRUNCATED]",
"description": "[DEPTH_TRUNCATED]",
"image": "[DEPTH_TRUNCATED]"
},
{
"@type": "[DEPTH_TRUNCATED]",
"name": "[DEPTH_TRUNCATED]",
"trialDesign": "[DEPTH_TRUNCATED]",
"description": "[DEPTH_TRUNCATED]",
"image": "[DEPTH_TRUNCATED]"
},
{
"@type": "[DEPTH_TRUNCATED]",
"name": "[DEPTH_TRUNCATED]",
"trialDesign": "[DEPTH_TRUNCATED]",
"description": "[DEPTH_TRUNCATED]",
"image": "[DEPTH_TRUNCATED]"
},
{
"@type": "[DEPTH_TRUNCATED]",
"name": "[DEPTH_TRUNCATED]",
"trialDesign": "[DEPTH_TRUNCATED]",
"description": "[DEPTH_TRUNCATED]",
"image": "[DEPTH_TRUNCATED]"
}
],
"prescriptionStatus": "https://health-lifesci.schema.org/PrescriptionOnly",
"dosageForm": "tablets",
"administrationRoute": "oral",
"doseSchedule": {
"@type": "DoseSchedule",
"frequency": "XTANDI is taken by mouth and is available in 2 dosage strengths: 40 mg and 80 mg. Take XTANDI once a day, at the same time every day, with or without food."
},
"offers": {
"@type": "Offer",
"price": "0",
"priceCurrency": "USD",
"url": "https://www.xtandi.com/"
},
"manufacturer": {
"@type": "Organization",
"name": "Astellas",
"logo": "https://www.xtandi.com/img/logo-astellas.png"
}
}
]
},
"_truncated": true,
"_original_size": 15978
}
/talking-to-your-doctor/
{
"@context": "http://schema.org",
"@type": "MedicalWebPage",
"audience": "https://schema.org/Patient",
"specialty": "https://schema.org/Oncologic",
"url": "https://www.xtandi.com/talking-to-your-doctor",
"name": "XTANDI® (enzalutamide) Doctor Discussion Guide",
"headline": "Questions for your next appointment",
"description": "See the XTANDI® Doctor Discussion Guide, which includes questions for your doctor about advanced prostate cancer and XTANDI®. See Safety Info, Risks, & Benefits.",
"potentialAction": [
{
"@type": "downloadAction",
"name": "Download this guide",
"url": "https://www.xtandi.com/pdf/xtandi-doctor-discussion-guide.pdf"
},
{
"@type": "Action",
"name": "Explore resources",
"url": "https://www.xtandi.com/patient-resources"
},
{
"@type": "Action",
"name": "Watch their stories",
"url": "https://www.xtandi.com/patient-videos"
},
{
"@type": "Action",
"name": "Sign up",
"url": "https://www.xtandi.com/support-sign-up"
}
],
"about": [
{
"@type": "Drug",
"name": "XTANDI",
"nonProprietaryName": "enzalutamide",
"image": {
"@type": "ImageObject",
"name": "XTANDI® (enzalutamide) 40 mg tablets | 80 mg tablets",
"description": "XTANDI Logo",
"contentUrl": "https://www.xtandi.com/images/xtandi-logo.svg"
},
"description": "What is XTANDI? XTANDI is a prescription medicine used to treat men with prostate cancer that: no longer responds to a hormone therapy or surgical treatment to lower testosterone OR has spread to other parts of the body and responds to a hormone therapy or surgical treatment to lower testosterone OR has not spread to other parts of the body and responds to a hormone therapy or surgical treatment to lower testosterone, and who are at high risk of cancer spreading to other parts of the body. It is not known if XTANDI is safe and effective in females or children.",
"prescribingInfo": "https://www.astellas.us/docs/us/12A005-ENZ-WPI.pdf",
"warning": "What should I tell my doctor before taking XTANDI? Tell your doctor about all your medical conditions, including if you: Have a history of seizures, brain injury, stroke, or brain tumors. Have a history of heart disease, have high blood pressure, or have abnormal amounts of fat or cholesterol in your blood (dyslipidemia). Are pregnant or plan to become pregnant. XTANDI can cause harm to your unborn baby and loss of pregnancy (miscarriage). Have a partner who is pregnant or may become pregnant. Males who have female partners who are able to become pregnant should use effective birth control (contraception) during treatment with XTANDI and for 3 months after the last dose. Males must use a condom during sex with a pregnant female. Are breastfeeding or plan to breastfeed. It is not known if XTANDI passes into your breast milk. Take other medicines. XTANDI may affect the way other medicines work, and other medicines may affect how XTANDI works. These include prescription and over-the-counter medicines, vitamins, and herbal supplements. Do not start or stop any medicine without talking to your doctor. How should I take XTANDI? Take XTANDI exactly as your doctor tells you. Take your prescribed dose once a day, at the same time each day. XTANDI can be taken with or without food. Swallow XTANDI capsules or tablets whole. Do not chew, dissolve, or open the capsules. Do not cut, crush or chew the tablets. Your doctor may change your dose if needed. Do not change or stop taking your prescribed dose of XTANDI without talking with your doctor first. If you are receiving gonadotropin-releasing hormone (GnRH) therapy, you should continue with this treatment while taking XTANDI unless you have had surgery to lower the amount of testosterone in your body (surgical castration). If you miss a dose of XTANDI: Take your prescribed dose as soon as you remember that day. If you miss your daily dose, take your prescribed dose at your regular time the next day. Do not take more than your prescribed dose of XTANDI each day. If you take too much XTANDI: Call your doctor or go to the nearest emergency room right away. You may have an increased risk of seizure if you take too much XTANDI. What are the possible side effects of XTANDI? XTANDI may cause serious side effects including: Seizure. If you take XTANDI, you may be at risk of having a seizure. Avoid activities where a sudden loss of consciousness could seriously harm you or someone else. Tell your doctor right away if you lose consciousness or have a seizure. Posterior Reversible Encephalopathy Syndrome (PRES). If you take XTANDI you may be at risk of developing a condition involving the brain called PRES. Tell your doctor right away if you have a seizure or quickly worsening symptoms such as headache, decreased alertness, confusion, reduced eyesight, blurred vision or other visual problems. Your doctor will do a test to check for PRES. Allergic Reactions. Allergic reactions have happened in people who take XTANDI. Stop taking XTANDI and get medical help right away if you develop swelling of the face, tongue, lip or throat. Heart Disease. Blockage of the arteries in the heart (ischemic heart disease) that can lead to death has happened in some people during treatment with XTANDI. Your doctor will monitor you for signs and symptoms of heart problems during your treatment. Call your doctor or go to the emergency room right away if you get chest pain or discomfort at rest or with activity or shortness of breath during your treatment with XTANDI. Falls and Bone Fractures. XTANDI treatment may increase your risk for falls and bone fractures. Falls were not caused by loss of consciousness or seizures. Your doctor will monitor your risks for falls and bone fractures during treatment with XTANDI. Your doctor will stop treatment with XTANDI if you have serious side effects. The most common side effects of XTANDI include: Muscle and joint pain Feeling more tired than usual Hot flashes Constipation Decreased appetite Diarrhea High blood pressure Bleeding problems Falls Bone fractures Headache XTANDI may cause fertility problems in males, which may affect the ability to father children. Talk to your doctor if you have concerns about fertility. These are not all the possible side effects of XTANDI. For more information, talk to your doctor or pharmacist. Call your doctor for medical advice about side effects. You may report side effects to the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. For further information, please talk to your doctor and click here for Patient Information and Full Prescribing Information for XTANDI.",
"prescriptionStatus": "https://health-lifesci.schema.org/PrescriptionOnly",
"dosageForm": "tablets",
"administrationRoute": "oral",
"doseSchedule": {
"@type": "DoseSchedule",
"frequency": "XTANDI is taken by mouth and is available in 2 dosage strengths: 40 mg and 80 mg. Take XTANDI once a day, at the same time every day, with or without food."
},
"offers": {
"@type": "Offer",
"price": "0",
"priceCurrency": "USD",
"url": "https://www.xtandi.com/"
},
"manufacturer": {
"@type": "Organization",
"name": "Astellas",
"logo": "https://www.xtandi.com/img/logo-astellas.png"
}
}
]
}
/support-sign-up/
{
"@context": "http://schema.org",
"@type": "MedicalWebPage",
"audience": "https://schema.org/Patient",
"specialty": "https://schema.org/Oncologic",
"url": "https://www.xtandi.com/support-sign-up",
"name": "XTANDI® (enzalutamide) Support Sign Up",
"headline": "Want to learn more about XTANDI? We're here to help",
"description": "Sign up to receive educational resources for XTANDI® (enzalutamide). See Important Safety Information, Risks, and Benefits.",
"potentialAction": [
{
"@type": "Action",
"name": "Review FAQs",
"description": "Frequently asked questions",
"url": "https://www.xtandi.com/faqs"
},
{
"@type": "Action",
"name": "Watch their stories",
"description": "Hear firsthand from men who are taking XTANDI",
"url": "https://www.xtandi.com/patient-videos"
},
{
"@type": "Action",
"name": "Explore resources",
"description": "Helpful XTANDI resources for patients and caregivers",
"url": "https://www.xtandi.com/patient-resources"
}
],
"about": [
{
"@type": "Drug",
"name": "XTANDI",
"nonProprietaryName": "enzalutamide",
"image": {
"@type": "ImageObject",
"name": "XTANDI® (enzalutamide) 40 mg tablets | 80 mg tablets",
"description": "XTANDI Logo",
"contentUrl": "https://www.xtandi.com/images/xtandi-logo.svg"
},
"description": "What is XTANDI? XTANDI is a prescription medicine used to treat men with prostate cancer that: no longer responds to a hormone therapy or surgical treatment to lower testosterone OR has spread to other parts of the body and responds to a hormone therapy or surgical treatment to lower testosterone OR has not spread to other parts of the body and responds to a hormone therapy or surgical treatment to lower testosterone, and who are at high risk of cancer spreading to other parts of the body. It is not known if XTANDI is safe and effective in females or children.",
"prescribingInfo": "https://www.astellas.us/docs/us/12A005-ENZ-WPI.pdf",
"warning": "What should I tell my doctor before taking XTANDI? Tell your doctor about all your medical conditions, including if you: Have a history of seizures, brain injury, stroke, or brain tumors. Have a history of heart disease, have high blood pressure, or have abnormal amounts of fat or cholesterol in your blood (dyslipidemia). Are pregnant or plan to become pregnant. XTANDI can cause harm to your unborn baby and loss of pregnancy (miscarriage). Have a partner who is pregnant or may become pregnant. Males who have female partners who are able to become pregnant should use effective birth control (contraception) during treatment with XTANDI and for 3 months after the last dose. Males must use a condom during sex with a pregnant female. Are breastfeeding or plan to breastfeed. It is not known if XTANDI passes into your breast milk. Take other medicines. XTANDI may affect the way other medicines work, and other medicines may affect how XTANDI works. These include prescription and over-the-counter medicines, vitamins, and herbal supplements. Do not start or stop any medicine without talking to your doctor. How should I take XTANDI? Take XTANDI exactly as your doctor tells you. Take your prescribed dose once a day, at the same time each day. XTANDI can be taken with or without food. Swallow XTANDI capsules or tablets whole. Do not chew, dissolve, or open the capsules. Do not cut, crush or chew the tablets. Your doctor may change your dose if needed. Do not change or stop taking your prescribed dose of XTANDI without talking with your doctor first. If you are receiving gonadotropin-releasing hormone (GnRH) therapy, you should continue with this treatment while taking XTANDI unless you have had surgery to lower the amount of testosterone in your body (surgical castration). If you miss a dose of XTANDI: Take your prescribed dose as soon as you remember that day. If you miss your daily dose, take your prescribed dose at your regular time the next day. Do not take more than your prescribed dose of XTANDI each day. If you take too much XTANDI: Call your doctor or go to the nearest emergency room right away. You may have an increased risk of seizure if you take too much XTANDI. What are the possible side effects of XTANDI? XTANDI may cause serious side effects including: Seizure. If you take XTANDI, you may be at risk of having a seizure. Avoid activities where a sudden loss of consciousness could seriously harm you or someone else. Tell your doctor right away if you lose consciousness or have a seizure. Posterior Reversible Encephalopathy Syndrome (PRES). If you take XTANDI you may be at risk of developing a condition involving the brain called PRES. Tell your doctor right away if you have a seizure or quickly worsening symptoms such as headache, decreased alertness, confusion, reduced eyesight, blurred vision or other visual problems. Your doctor will do a test to check for PRES. Allergic Reactions. Allergic reactions have happened in people who take XTANDI. Stop taking XTANDI and get medical help right away if you develop swelling of the face, tongue, lip or throat. Heart Disease. Blockage of the arteries in the heart (ischemic heart disease) that can lead to death has happened in some people during treatment with XTANDI. Your doctor will monitor you for signs and symptoms of heart problems during your treatment. Call your doctor or go to the emergency room right away if you get chest pain or discomfort at rest or with activity or shortness of breath during your treatment with XTANDI. Falls and Bone Fractures. XTANDI treatment may increase your risk for falls and bone fractures. Falls were not caused by loss of consciousness or seizures. Your doctor will monitor your risks for falls and bone fractures during treatment with XTANDI. Your doctor will stop treatment with XTANDI if you have serious side effects. The most common side effects of XTANDI include: Muscle and joint pain Feeling more tired than usual Hot flashes Constipation Decreased appetite Diarrhea High blood pressure Bleeding problems Falls Bone fractures Headache XTANDI may cause fertility problems in males, which may affect the ability to father children. Talk to your doctor if you have concerns about fertility. These are not all the possible side effects of XTANDI. For more information, talk to your doctor or pharmacist. Call your doctor for medical advice about side effects. You may report side effects to the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. For further information, please talk to your doctor and click here for Patient Information and Full Prescribing Information for XTANDI.",
"prescriptionStatus": "https://health-lifesci.schema.org/PrescriptionOnly",
"dosageForm": "tablets",
"administrationRoute": "oral",
"doseSchedule": {
"@type": "DoseSchedule",
"frequency": "XTANDI is taken by mouth and is available in 2 dosage strengths: 40 mg and 80 mg. Take XTANDI once a day, at the same time every day, with or without food."
},
"offers": {
"@type": "Offer",
"price": "0",
"priceCurrency": "USD",
"url": "https://www.xtandi.com/"
},
"manufacturer": {
"@type": "Organization",
"name": "Astellas",
"logo": "https://www.xtandi.com/img/logo-astellas.png"
}
}
]
}
Your Diagnosis
Before revealing the machine’s verdict, predict the BS score for each signal. Higher = more BS (more fluff, less verifiable substance). Drag each slider, then submit to compare your judgment against the engine.
Information Density
0 / 30
Read the Narrative & headings: do hard facts (prices, dates, numbers) outweigh fluff power-words?
Semantic Coherence
0 / 20
Compare the homepage promise against the sub-page reality. Do they hold the same line?
Trust & Proof
0 / 20
Weigh review mentions against actual external proof links. Claims without verification = theatre.
Commodity Fingerprint
0 / 15
Check headings & narrative against the industry clichés in the setup above.
Identity & Authority
0 / 15
Inspect the schema: is there real Organization/Person identity with sameAs links, or gaps?
Your predicted BS score
0 / 100
Stuck? Reveal the heuristic lens — how the deterministic page-auditor reads each signal (no AI, pure pattern rules)
These are the structural rules a local, deterministic auditor applies — the same lens you can use to judge each signal. They describe what to look for, not this company’s result.
Information Density
Classify each sentence as substantive or hollow. Grounding markers — numbers, currencies, dates, technical units, named entities — outweigh marketing adjectives. When fluff sits right next to hard evidence, the fluff is forgiven.
Semantic Alignment
Pull the main entities out of the H1, then check whether they actually recur through the body. A page that announces one thing and then talks about another drifts. Headings with no real sentences underneath read as pseudo-substance.
Trust & Proof
Count trust words (review, testimonial, rating, verified) against real outbound proof links (Google, Trustpilot, Clutch, G2, Yelp). Lots of trust language with zero verification links is trust theatre. Unlinked logo galleries count against it.
Commodity Fingerprint
Look at how much sentence length varies. Natural writing varies its rhythm; templated or mass-produced copy is statistically uniform. Very low variation reads as commodity content — unless unique named entities break the pattern.
Identity & Authority
Inspect the JSON-LD. Is there an Organization or Person schema, and does it carry sameAs links to real external profiles (LinkedIn, socials)? Missing schema or no identity declaration signals an anonymous entity.
Want to apply this lens yourself? The free BS Indicator Chrome extension runs these heuristic checks live on any page. Bear in mind it is a single-page, deterministic tool — it relies only on pattern rules for the page in front of it and does not perform the cross-page semantic correlation this audit uses, so its readout is a starting lens, not the full verdict.
B
BS Level
Medical Devices, Pharma & Biotech
40.7 Avg BS
Based on 784 businesses audited.
BS Detector
Medical Devices, Pharma & Biotech BS: XTANDI (Astellas Pharma Inc.) (xtandi.com)
https://xtandi.com
📍 Industry: Medical Devices, Pharma & Biotech
11
BS / 100
This is a high-integrity medical website that prioritizes regulatory transparency over marketing hyperbole. The BS score of 11 reflects a site that provides substantial evidence for every claim, with only minor points lost to necessary repetition and standard patient-engagement terminology. It is an authoritative resource for both patients and healthcare providers.
Info Density
Power-words vs. Substance ratio.
6
20% BS
Semantic Coherence
Homepage promise vs. Sub-page reality.
0
0% BS
Trust & Proof
Verifiable evidence vs. Trust Theatre.
2
10% BS
Commodity Fingerprint
Detection of industry clichés/templates.
3
20% BS
Identity & Authority
Expert verifiability & Schema depth.
0
0% BS
Incorporate National Clinical Trial (NCT) identifiers into each clinical results section to allow for one-click verification of raw data on government registries. Replace marketing-heavy headings like ‘Real XTANDI Xperiences’ with ‘Patient Case Study Videos’ to better align with the clinical tone of the rest of the site. Include specific peer-reviewed journal citations (e.g., NEJM or Lancet) next to the 5-year survival statistics. Add a technical glossary explaining the statistical difference between ‘median’ and ‘average’ to further empower high-literacy patients and reduce perceived ambiguity.
The website perfectly aligns with the Pharmaceutical and Biotech industry, specifically within the oncology therapeutic area. The presence of extensive Important Safety Information (ISI), clinical trial data sets, and regulatory approval claims confirms its classification.
“The BS score was driven by Pillar 1 (Information Density) due to the high repetition of the core regulatory claim and Pillar 4 (Commodity Fingerprint) due to the use of standard pharmaceutical marketing jargon. Pillar 3 (Trust and Proof) contributed 2 points because the patient stories lack verified external proof links, despite the high quality of the surrounding clinical data.”
Verified Analysis Date: June 20, 2026
© 1EuroSEO Independent Evaluator — Non-Sponsored Result
Analysis Disclosure & Source Attribution
This training module utilizes a snapshot of public data from XTANDI (Astellas Pharma Inc.), captured on June 20, 2026, to demonstrate how machine logic evaluates different types of business narratives.
Purpose: This data is presented under “Fair Use” / “Educational Exception” for the purpose of forensic semantic analysis, allowing users to compare human intuition against machine-generated evaluations.
Notice to XTANDI (Astellas Pharma Inc.): This analysis is part of a non-adversarial audit conducted by 1 Euro SEO. The results provided by 1EuroSEO are intended as professional feedback to help improve any website’s machine-readability and authority signals. The 1EuroSEO BS Detection Tool is a free tool, and anyone can test any company to see how their content is interpreted by AI models.
Any company can use the insights for free and improve its voice by comparing it to industry clichés or competitors. When a company has updated its content, it can always submit a new audit request, which will be reflected in a new current score.
To all users: You are encouraged to visit the live site at https://xtandi.com to view the most current version of its content and learn from the source what this company is about and what it offers.